Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 17/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 12/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1249736 | 0.94 | JAK2 (0.42) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL1249466 | 0.90 | JAK2 (0.52) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL3510611 | 0.86 | JAK2 (0.59) | JAK2JAK3KCNH2 | |
| SCHEMBL3510613 | 0.80 | JAK2 (0.59) | JAK2JAK3KCNH2 | |
| SCHEMBL13537091 | 0.79 | IKBKE (0.32) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL1249350 | 0.78 | JAK2 (0.45) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL2181092 | 0.78 | JAK2 (0.42) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL1249280 | 0.78 | TBK1 (0.46) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL1248277 | 0.78 | JAK2 (0.44) | JAK2JAK3KCNH2TBK1IKBKE | |
| SCHEMBL14686175 | 0.78 | TBK1 (0.42) | JAK2JAK3KCNH2TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | claimed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | claimed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | claimed |
| EP-2278969-B1 | Inhibitors of Janus kinases | MERCK SHARP & DOHME (US) | 2013-02-13 | — | — | EP | disclosed |
| US-8278335-B2 | Inhibitors of Janus kinases | MERCK SHARP & DOHME CORP. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166129-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885KCNH2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.